GlassScriptPhysician profile
Samim Enayat
NPI 1700053824
$217,122.71
in general payments reported to CMS, 2019-2025
24 companies · $26K in 2025
The $26K reported for 2025 was more than what 94% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $50K · 2020: $22K · 2021: $27K · 2022: $58K · 2023: $20K · 2024: $14K · 2025: $26K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $59K · Food and Beverage: $932 · Travel and Lodging: $522.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $58,677.07 |
| Food and Beverage | $931.79 |
| Travel and Lodging | $522.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $155,198.31 | 2019-2025 | Ozempic, Rybelsus |
| Sanofi-Aventis U.S. LLC | $54,970.70 | 2019-2023 | |
| Dexcom, INC. | $5,516.50 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $334.02 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $165.39 | 2019-2021 | |
| Mannkind Corporation | $145.19 | 2019-2020 | |
| Companion Medical, INC. | $107.52 | 2019-2020 | |
| Lilly USA, LLC | $90.00 | 2019 | |
| Ibsa Pharma INC. | $82.33 | 2019-2021 | |
| Amgen INC. | $73.79 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $59.86 | 2020-2021 | |
| Abbvie INC. | $46.07 | 2020 | |
| Medtronic Minimed, INC. | $44.06 | 2020 | |
| Janssen Pharmaceuticals, INC | $41.54 | 2019-2020 | |
| Antares Pharma, INC. | $37.36 | 2019-2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $35.99 | 2020 | |
| Tandem Diabetes Care, INC. | $32.11 | 2019 | |
| Insulet Corporation | $28.10 | 2019-2020 | |
| Horizon Therapeutics Plc | $23.63 | 2019 | |
| Abbott Laboratories | $23.14 | 2020 | |
| Amarin Pharma, INC. | $22.85 | 2019 | |
| Radius Health, INC. | $20.48 | 2021 | |
| Xeris Pharmaceuticals, INC. | $12.33 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $11.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samim Enayat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.